Clinical Trial Update: FOLFIRI Versus Docetaxel and Cisplatin as a Second-line Chemotherapy After Failure of First-line Chemotherapy in Advanced Gastric Cancer [Phase 3]

View source ↗

Summary

This Phase 3 clinical trial compares FOLFIRI versus Docetaxel plus Cisplatin as second-line chemotherapy after first-line therapy failure in advanced gastric ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• CISPLATIN (cisplatin)
• DOCETAXEL (DOCETAXEL)
• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)

Snippet

Sponsor: Yonsei University | Conditions: Inoperable Gastric Cancer | Phase 3 | Status: COMPLETED